Crohn’s Disease And CBD
Crohn’s Disease, is a serious form of Inflammatory Bowel Disease (IBD). It is caused by a combination of various environmental and genetic factors, in addition to a person’s immune system. This disease can be uncomfortable, painful and debilitating and there is no cure for it.
Crohn’s affects more than half a million American’s digestive tract – which results in extreme weight loss, severe vomiting, bloody stool, diarrhea and abdominal pain. It may also result in arthritis as well as eye and skin conditions.
Cannabidiol (CBD) is mainly found in hemp. It is currently available legally in all fifty states following the passage in 2015 of the Industrial Hemp Farming Act. It is making major strides as a possible treatment for Crohn’s as well as other types of gastrointestinal diseases.
The following are abstracts from three promising studies published by the National Institute for Health that relate to Crohns, Colitis and CBD:
Cannabidiol in inflammatory bowel diseases
The mini review highlights the significance of cannabidiol (CBD) as a potentially therapeutic drug for IBD (inflammatory bowel diseases). Actual IBD pharmacological treatments need to be expanded towards searching for low-cost and low-toxicity drugs that can be given by themselves or in combination with conventional anti-IBD drugs for increasing their efficacy during therapy for relapsing types of colitis. Cannabis preparations in the past have been considered to be promising new pharmacological tools given their anti-inflammatory role for IBD in addition to other kinds of gut problems. However, due to their psychotropic effect, their use for clinical therapy has been severely limited. CBD is an extremely promising compound given that is shares the common cannabinoid beneficial effects on the gut and also lacks having any psychotropic effects. Its activity for years has been mysterious for both pharmacologists and gastroenterologists. However, it is now clear that the compound might interact at extra-cannabinoid receptor system sites, like peroxisome proliferator-activated receptor-gamma. What makes CBD such as a promising candidate for developing a new anti-IBD drug class in this strategic interaction.
Cannabidiol, a non-psychotropic and safe ingredient of the Cannabis sativa marijuana plant
Millions of individuals are affected by inflammatory bowel disease. However, the pharmacological treatments that are available are unsatisfactory and disappointing. Cannabidiol, a non-pschotropic and safe marijuana ingredient, exerts mechanisms (e.g. inhibits endocannabinoids enzymatic degradation) and pharamalogical effects (e.g. antioxidants) that potentially benefit an inflamed gut. Therefore, we investigated the effects of cannabidiol within a colitis murine model. Colitis was induced within mice by administering dinitrobenzene sulfonic acid. Assessment of inflammation was made both histologically and macroscopically. Inside the inflamed colon, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 were evaluated by endocannabinoids via isotope dilution liquid chromatography-mass spectrometry, interleukin-10 via ELISA, interleukin-1beta and Western blot. The effect that cannabidiol had on oxidative stress was evaluating using human colon adenocarcinoma (Caco-2) cells. Cannabidiol reduced colon injuries as well as endocannabinoid, interleukin-10, interleukin-1beta, and inducible iNOS (however not cyclooxygenase-2) expression changes associated with 6, 4 2-dinitrobenzene sulfonic acid administration. Within Caco-2 cells, lipid peroxidation and reactive oxygen species production were reduced by cannabidiol. In conclusion, the likely safe compound cannabidiol, prevents experimental colitis within mice.
Systemic and topical cannabidiol improves trinitrobenzene sulfonic acid colitis within mice
Aims and Background:
It is now that Cannabis sativa compounds exert anti-inflammatory properties, and some of these do not induce any psychotropic side effects. One side effect-free phytocannabinoid is Cannabidiol (CBD). When given intraperitoneally, it improves chemically induced colitis within rodents. We tested here the possibility of whether oral and rectal application of CBD could ameliorate colonic inflammation as well, since these types of application might represent a better way to deliver drugs within the human colitis.
Trinitrobenzene sulfonic acid was used to induce colitis in CD1 mice. Individual groups were treated with CBD either intrarectally (20 mg/kg), orally (20 mg/kg) or intraperitoneally (10 mg/kg). The myeloperoxidase (MPO) assay, histopathology and macroscopic scoring were used to evaluate colitis.
Intraperitoneal CBD treatment of mice resulted in improved colonic inflamation. Intrarectal CBD treatment resulted in a decrease in MPO activity and significant improvement in disease parameters. Oral treatment, which used the same dose as with rectum, did not have an ameliorating effect on colitis in mice.
The data from this study indicates that intrarectal cannabinoid delivery, as well as intraperitoneal application, might be a very useful therapeutic administration method to take for treating colonic inflammation.